Cargando…
Public Health Outcomes May Differ After Switching from Brand-Name to Generic Angiotensin II Receptor Blockers
BACKGROUND: It is unclear whether generics are as safe as brand-name drugs in cardiology. For public health surveillance purposes, we evaluated if switching from the brand-name losartan, valsartan, or candesartan impacted the occurrence of the following outcomes: emergency room (ER) consultations, h...
Autores principales: | Leclerc, Jacinthe, Blais, Claudia, Rochette, Louis, Hamel, Denis, Guénette, Line, Beaudoin, Claudia, Poirier, Paul |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7221012/ https://www.ncbi.nlm.nih.gov/pubmed/32342284 http://dx.doi.org/10.1007/s40268-020-00307-2 |
Ejemplares similares
-
Brand Name Versus Generic?
por: Aungaroon, Gewalin
Publicado: (2023) -
Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
por: Bosak, Magdalena, et al.
Publicado: (2017) -
Appearances of Premature Atrial and Ventricular Contractions After Switching From Brand Name to Generic Cibenzoline
por: Oguri, Gaku, et al.
Publicado: (2023) -
The concept of: Generic drugs and patented drugs vs. brand name drugs and non-proprietary (generic) name drugs
por: Thakkar, Karan B., et al.
Publicado: (2013) -
Generic versus brand-name drugs used in cardiovascular diseases
por: Manzoli, Lamberto, et al.
Publicado: (2015)